2,864 Shares in Novartis AG (NYSE:NVS) Bought by one8zero8 LLC

one8zero8 LLC bought a new position in Novartis AG (NYSE:NVS - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 2,864 shares of the company's stock, valued at approximately $279,000.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Centaurus Financial Inc. grew its stake in Novartis by 1.7% in the 3rd quarter. Centaurus Financial Inc. now owns 5,728 shares of the company's stock worth $659,000 after acquiring an additional 98 shares during the period. Bryn Mawr Capital Management LLC grew its stake in Novartis by 0.8% in the 4th quarter. Bryn Mawr Capital Management LLC now owns 12,884 shares of the company's stock worth $1,254,000 after acquiring an additional 100 shares during the period. Rothschild Investment LLC grew its stake in Novartis by 0.6% in the 4th quarter. Rothschild Investment LLC now owns 16,682 shares of the company's stock worth $1,623,000 after acquiring an additional 101 shares during the period. Meridian Wealth Management LLC grew its stake in Novartis by 2.6% in the 4th quarter. Meridian Wealth Management LLC now owns 4,161 shares of the company's stock worth $405,000 after acquiring an additional 106 shares during the period. Finally, Angeles Wealth Management LLC grew its stake in Novartis by 3.5% in the 4th quarter. Angeles Wealth Management LLC now owns 3,249 shares of the company's stock worth $316,000 after acquiring an additional 110 shares during the period. 13.12% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

NVS has been the subject of several recent analyst reports. Barclays reaffirmed an "underweight" rating on shares of Novartis in a research note on Monday, February 3rd. Morgan Stanley assumed coverage on shares of Novartis in a report on Wednesday, February 12th. They issued an "underweight" rating on the stock. HSBC lowered shares of Novartis from a "hold" rating to a "reduce" rating in a report on Wednesday, December 4th. Deutsche Bank Aktiengesellschaft upgraded shares of Novartis from a "hold" rating to a "buy" rating in a report on Tuesday, February 4th. Finally, UBS Group reiterated a "neutral" rating on shares of Novartis in a report on Thursday, February 13th. Three research analysts have rated the stock with a sell rating, six have assigned a hold rating, one has given a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus target price of $123.38.

Remove Ads

Novartis Stock Up 1.6 %

Shares of NYSE:NVS traded up $1.79 during midday trading on Thursday, hitting $113.35. 5,885,645 shares of the company's stock traded hands, compared to its average volume of 1,458,279. The company has a debt-to-equity ratio of 0.48, a quick ratio of 0.84 and a current ratio of 1.04. The company has a market cap of $231.68 billion, a PE ratio of 19.28, a P/E/G ratio of 1.70 and a beta of 0.53. The firm's fifty day moving average price is $106.14 and its two-hundred day moving average price is $107.50. Novartis AG has a twelve month low of $92.35 and a twelve month high of $120.92.

Novartis (NYSE:NVS - Get Free Report) last released its quarterly earnings results on Friday, January 31st. The company reported $1.98 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.80 by $0.18. Novartis had a net margin of 23.56% and a return on equity of 37.24%. On average, equities research analysts anticipate that Novartis AG will post 8.45 EPS for the current fiscal year.

Novartis Announces Dividend

The company also recently declared a dividend, which was paid on Wednesday, March 12th. Investors of record on Wednesday, March 12th were paid a dividend of $3.8695 per share. The ex-dividend date of this dividend was Wednesday, March 12th. Novartis's dividend payout ratio (DPR) is 42.69%.

Novartis Profile

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.